Published • loading... • Updated
Second life for a gene therapy; Takeda passes Phase 2/3 test; UK cancer biotech's $83M raise
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Second life for a gene therapy; Takeda passes Phase 2/3 test; UK cancer biotech's $83M raise
A blood test might predict who will respond to Wegovy; Viridian's thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Cleveland-based biotech called ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
FactualityÂ
To view factuality data please Upgrade to Premium
